skip to main content

Recurrent VTE Cancer — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardGI CancersRecurrent VTE CancerSCE Medical Oncology

A 55-year-old woman with metastatic pancreatic cancer on gemcitabine + nab-paclitaxel develops persistent bilateral lower limb DVTs despite therapeutic anticoagulation with LMWH. She has failed two different anticoagulants. What approach should be considered?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: E — Increase LMWH dose by 25-30% (dose-escalation for cancer-associated recurrent VTE) or switch to an alternative agent; consider IVC filter only if anticoagulation is failing despite dose escalation

Recurrent VTE despite therapeutic anticoagulation occurs in approximately 6-9% of cancer patients. Management includes: (1) verify adherence and adequate dosing, (2) dose-escalate LMWH by 20-25% (or switch from DOAC to LMWH), (3) consider IVC filter as an adjunct (not replacement) to anticoagulation if recurrence occurs despite dose escalation. The ISTH/ASH guidelines support dose-escalation as first-line for recurrent cancer-associated VTE. IVC filters alone do not reduce PE mortality and carry long-term complications.

Reference: NICE NG158; ISTH Cancer VTE Guidelines 2023; ESMO Supportive Care